President and CEO
Joe Ciaffoni was appointed President and Chief Executive Officer of Collegium Pharmaceutical in July 2018. Joe Ciaffoni joined Collegium Pharmaceutical in May 2017 as Executive Vice President and Chief Operating Officer. Prior to joining the Collegium, Mr. Ciaffoni, served as President, U.S. Branded Pharmaceuticals of Endo International plc. Before that, Mr. Ciaffoni held various positions of increasing responsibility at Biogen Idec, including Senior Vice President, Global Specialty Medicines Group, Senior Vice President, U.S. Commercial and Vice President, U.S. Neurology Field Operations and Marketing. Prior to joining Biogen Idec, Mr. Ciaffoni was Executive Vice President and Chief Operating Officer of Shionogi Inc. and President of Shionogi Pharmaceuticals. Mr. Ciaffoni also previously served as Vice President, Sales for Schering-Plough (now Merck) and held several commercial leadership roles at Sanofi-Synthelabo (now Sanofi) and Novartis. Mr. Ciaffoni received a B.A. in Communications and an M.B.A. from Rutgers.
ALISON B. FLEMING, Ph.D.
Chief Technology Officer
Dr. Alison Fleming joined Collegium Pharmaceutical in 2002, shortly after completing her Ph.D. in the School of Chemical and Biomolecular Engineering at Cornell University. Prior to joining Collegium, her academic research focused on implantable drug delivery systems for cancer therapy. Dr. Fleming is an inventor on several United States Patents and pending patent applications, and has authored numerous scientific publications and poster presentations in the field of novel drug delivery systems. In 2001 she was the recipient of the Jorge Heller Journal of Controlled Release Outstanding Paper Award. She received her B.S. degree in Chemical Engineering from the University of Massachusetts, Amherst.
Executive Vice President and Chief Financial Officer
Paul Brannelly joined Collegium Pharmaceutical in February 2015 as Executive Vice President and Chief Financial Officer. Prior to joining Collegium, Paul held senior financial management positions for both publicly held and privately held companies, gaining significant experience raising capital, executing growth strategies and mergers and acquisitions. Paul most recently served as Senior Vice President, Finance & Administration, and Treasurer of Karyopharm Therapeutics Inc., a publicly traded, clinical-stage pharmaceutical company. Prior to Karyopharm, Paul served as Vice President Finance, Treasurer, and Secretary for Verastem, Incorporated, a publicly traded biotechnology company. Earlier in his career, Paul was Chief Financial Officer of Longwood Fund, a healthcare dedicated venture capital fund, and also held senior financial management roles with Sirtris Pharmaceuticals (acquired by GlaxoSmithKline), CombinatoRx and Dyax. With 18 years in the biopharmaceutical industry, Paul has raised $1.0 billion in public and private capital. Paul holds a Bachelors in Business Administration in Accounting from University of Massachusetts at Amherst and was a Certified Public Accountant.
Executive Vice President and Chief Commercial Officer
Scott Dreyer was appointed Executive Vice President and Chief Commercial Officer in July 2018. Scott Dreyer joined Collegium in January 2018 as Senior Vice President of Sales, Marketing, Commercial Capabilities and Training. Scott has over 24 years of commercial experience across sales, marketing, commercial operations and strategic planning, all within the biopharma industry. Most recently, Scott was the Senior Vice President, Marketing and Commercial Operations for The Medicines Company, where he led all commercial functions and helped the organization advance their commercial capabilities, prepare for new product launches and strategically pivot the company through business development activities. Prior to joining The Medicines Company, Scott was the Vice President and Chief Marketing Officer-US at Biogen, leading the marketing activities for an ~$7 billion business spanning multiple therapeutic areas. Prior to Biogen, Scott held various commercial leadership positions of increasing responsibility at Merck & Co including: VP-US Hospital and Oncology Sales and Commercial Operations, VP-US Primary Care Sales, Executive Director US Regional Marketing Leader – Neuroscience, Executive Director Customer Marketing and Solutions, Sr. Director of Strategic Planning and Director of Cardiovascular Marketing. Throughout his career, Scott has been involved in the commercialization of over 35 products across more than 15 therapeutic areas, and launched over 20 products. Scott received his B.S. degree in Biology from Messiah College in Grantham, PA.
Executive Vice President and General Counsel
Shirley Kuhlmann joined Collegium Pharmaceutical in March 2018 as Executive Vice President, General Counsel and Secretary. Prior to joining Collegium, Ms. Kuhlmann was an attorney in the Health Sciences Group of Pepper Hamilton LLP, a law firm headquartered in Philadelphia, PA. Ms. Kuhlmann began her career at Pepper in 2007, as an associate, and was elected a partner of that firm in 2016. Throughout her career at Pepper, Ms. Kuhlmann advised private and public companies on a range of transactional matters, including securities offerings, mergers & acquisitions, and other financing transactions. Ms. Kuhlmann received a B.A. in Economics and Political Science from Columbia University and a J.D. from the Emory University School of Law, where she was the Executive Managing Editor of the Emory Law Review.
Vice President, Marketing
Arun Padmanabhan joined Collegium in October of 2017 and currently serves as Vice President of Marketing. Arun has 20 years of commercial leadership experience in the pharmaceutical and biotechnology industry in various therapeutic areas including Cardiovascular, Multiple Sclerosis, Pediatrics, Men’s and Women’s Health, Diabetes, and Alzheimer’s. Prior to joining Collegium, Arun was the Senior Director of Marketing at Biogen, where he led multiple brands within their multiple sclerosis franchise in the US and globally. Before that, Arun was the Senior Director of Marketing and Commercial Operations for Amarin Inc., where he built the commercial organization to launch its first product. Arun also led marketing at Shionogi, Inc. Prior to that he held both marketing and sales leadership roles at Sanofi. Arun received a Bachelor of Science from Siena College and Masters in Business Administration from the University of Connecticut.
Vice President, Commercial Finance
David Coyne joined Collegium Pharmaceutical in November 2015 and currently serves as Vice President, Commercial Finance. Prior to joining Collegium, David served as Director, Commercial Finance at Cubist Pharmaceuticals, where he was responsible for leading the Third-Party Logistics, Distribution, Trade, Order to Cash, Gross to Net, Commercial FP&A, and Government Pricing and Reporting functions across Cubist’s portfolio of acute care products. David has been involved with the Launch of 7 products and several acquisitions throughout his career. Prior to Cubist, David held Director level positions in Finance at American Tower Corporation and the May Company. He received his B.A. in Political Science and Economics from the University of Massachusetts, Amherst.
DOUGLAS R. CARLSON
Vice President, Commercial Operations, Corporate Strategy & Business Development
Doug Carlson joined Collegium in March 2013 and currently serves as Vice President of Commercial Operations, Corporate Strategy & Business Development. During his tenure at Collegium, Doug also led the Strategic Commercial Channels (Hospital and Long Term Care Sales Organizations). Doug has over 16 years of experience with a multi-disciplinary background in M&A, venture capital, corporate finance, business development and commercial operations with both large and emerging growth healthcare companies. Prior to joining Collegium, Doug was Senior Director of Business Development at BTG International Inc. where he was responsible for global specialty pharmaceutical M&A and licensing. Prior to BTG, Doug was Senior Director and Head of Business Development for Lundbeck Inc., the U.S. Headquarters of H. Lundbeck A/S. Prior to Lundbeck, Doug was Director of Corporate Development and M&A at Ovation Pharmaceuticals, Inc., where he played an integral role in the sale of Ovation to Lundbeck in 2009. Prior to Ovation, Doug was an Associate in the healthcare group at Pequot Ventures, the venture capital arm of Pequot Capital Management, Inc. Doug started his career in the healthcare investing banking group of SG Cowen & Co. He received a Bachelor of Arts degree from Trinity College in Hartford, Connecticut.
Vice President, Sales
Jack Maroney joined Collegium Pharmaceutical in October 2015 as Vice President of Sales. Jack has more than 25 years of diverse pharmaceutical manufacturer experience in sales, national accounts, business analytics, marketing, managed markets, sales leadership, and building high performing sales teams. Prior to joining Collegium, Jack was Vice President of Specialty Markets Sales at Sunovion Pharmaceuticals, where he led a 200-person specialty sales team. At Sunovion, Jack served as Regional Business Manager, Marketing Director, National Account Director, Area Sales Director, and Regional Sales Director. Prior to Sunovion, Jack worked at Roche Laboratories where he held a variety of field sales roles such as Regional Account Director, Division Sales Manager, Business Unit Manager, Medical Center Representative, and Sales Representative. Jack received his Bachelor of Arts degree in Business and Economics from St. Anselm College and his MBA from Babson College.
JOHN WEET, Ph.D.
Vice President, Regulatory Affairs and Quality Assurance
Dr. John (Jack) Weet joined Collegium Pharmaceutical in June 2015 as Vice President, Regulatory Affairs and Quality Assurance. Prior to joining Collegium, Dr. Weet was Vice President of Regulatory Affairs at Durata Therapeutics, Vertex Pharmaceuticals, and Bausch and Lomb, where he was closely involved with the submissions of Dalvance® (dalbavancin), Incivek® (telaprevir), and Besivance® (besifloxicin), respectively. In addition, Dr. Weet was on the faculty of the Pharmaceutical Education and Research Institute (PERI), a guest lecturer at Georgia Institute of Technology, a member of the Long Island University Curriculum Planning Committee of the Arnold and Marie Schwartz College of Pharmacy, and has authored various papers and presentations at industry conferences. Dr. Weet is a graduate of St. Lawrence University and holds his Ph.D. in Medical Physiology from the Ohio State University.
Vice President, Market Access and Trade
Kevin O’Keeffe joined Collegium in July 2015 as Vice President of Market Access and Trade. Kevin has more than 15 years of experience spanning industry and consulting. Most recently, Kevin was Senior Director of Strategic Pricing, Access & Reimbursement at Cubist Pharmaceuticals where he was responsible for leading the pricing, managed care contracting, patient access, and payer marketing functions across Cubist’s portfolio of acute care medicines. Prior to joining Cubist, Kevin was a Principal with the life sciences consulting practice at Charles River Associates where he advised pharmaceutical clients on pricing strategy, managed care contracting, and payer marketing across a range of therapeutic areas. Prior to Charles River Associates, Kevin was a Principal with Hoffman Alvary & Company where he advised clients in connection with patent licensing transactions and patent licensing disputes. Kevin received his B.A. from Bowdoin College and his M.B.A. from Georgetown University.
MICHAEL DEGEORGE, PharmD
Vice President, Medical Affairs
Dr. Michael DeGeorge serves as Vice President of Medical Affairs for Collegium Pharmaceutical. Prior to joining Collegium in August of 2015, Dr. DeGeorge was the Director of Medical Affairs for Ameritox, where he a led a team of field-based scientists and oversaw the research and publication strategy. Prior to Ameritox he held Medical Affairs positions in the pharmaceutical industry, including positions at King Pharmaceuticals, Archimedes, and sanofi-aventis. Dr. DeGeorge has supported multiple pain medications, including multiple abuse-deterrent opioid formulations, and has presented original research at many scientific congresses. He earned a Bachelor’s degree in Pharmacy from St. John’s University in New York and a Doctor of Pharmacy Degree from the University of Florida.
SAID SAIM, Ph.D.
Vice President, Pharmaceutical Development
Said Saim holds a Ph.D. and a M.S. in Chemical Engineering from the University of Kansas. He was Assistant Research Professor at the Higuchi BioSciences Center for Drug Delivery Research in Lawrence, Kansas prior to joining Boehringer Ingelheim Pharmaceuticals, Inc. in 1996. At BIPI, Said was a Senior Principal Scientist and led a team of Engineers and Scientists in charge of process development, scale up and technology transfer of North American products. He joined Collegium Pharmaceutical in 2008 as a Senior Director of Pharmaceutical Development. Said has published 22 papers in Engineering and Science Journals and holds 18 patents.
Vice President, Supply Chain
Scott Sudduth joined Collegium Pharmaceutical in February 2018 as Vice President, Supply Chain. Prior to joining the Collegium, Scott served as Head of Supply Chain for Moderna Therapeutics. Before that, he spent more than 25 years in positions of increasing responsibility with Genzyme and Sanofi, most recently as Vice President, Global Supply Chain, where he managed the Sanofi Genzyme product portfolio. His experience includes E2E value chain management, external manufacturing operations, supply chain development, risk mitigation, CMC and business operations management. Scott started his career at Genzyme in 2001. Scott received his Bachelor of Science from Clarkson University.
STEVEN D. PASSIK, Ph.D.
Vice President, Scientific Affairs, Education and Policy
After a 25 year academic and clinical career at Memorial Sloan Kettering Cancer Center, University of Kentucky and Vanderbilt University, Dr. Passik spent the past 4 years in the toxicology and most recently the pharmaceutical industry. His research has focused on psychiatric aspects of cancer and non-cancer pain and symptom management and the interface of pain management and addiction. He has served as editor and reviewer for multiple journals in pain and psycho-oncology. He has authored over 200 scholarly publications.